Psychotic disorder induced by oxybutynin: Presentation of two cases
- PMID: 17163294
- DOI: 10.2165/00044011-200626100-00007
Psychotic disorder induced by oxybutynin: Presentation of two cases
Abstract
Anticholinergic agents are muscarinic receptor antagonists that suppress the activity of the acetylcholine system in the brain. Some of these agents also increase the concentration of dopamine in the synaptic cleft, which may result in psychotic symptoms. Oxybutynin is an antimuscarinic drug that may have adverse effects on the CNS, including memory impairment, confusion, delirium and hallucinations in elderly patients. To date, several case reports have been published about the association between oxybutynin and psychotic symptoms in elderly subjects, but we were unable to find any case reports describing oxybutynin-induced psychotic disorders in young people. Here we report on two patients, a 7-year-old boy and a 21-year-old man, who developed a brief psychotic disorder that may have been caused by oxybutynin. The first patient was kept under observation with vital functions supported but no medication. All his psychotic symptoms regressed and his general condition improved. The second patient was treated with olanzapine 10 mg/day. His psychotic symptoms resolved within 3 weeks. Our two case reports provide evidence that oxybutynin may induce psychotic disorders, and in younger patients.
Similar articles
-
Medication nonadherence secondary to drug-induced memory loss.Consult Pharm. 2010 Feb;25(2):117-21. doi: 10.4140/TCP.n.2010.117. Consult Pharm. 2010. PMID: 20211824
-
Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases.J Pediatr. 2009 Sep;155(3):432-4. doi: 10.1016/j.jpeds.2009.01.074. J Pediatr. 2009. PMID: 19732583
-
Hallucinations after hypospadias repair.J Pediatr Surg. 2006 Mar;41(3):e33-5. doi: 10.1016/j.jpedsurg.2005.12.039. J Pediatr Surg. 2006. PMID: 16516613
-
Transdermal oxybutynin: sticking to the facts.Eur Urol. 2007 Apr;51(4):907-14; discussion 914. doi: 10.1016/j.eururo.2006.11.033. Epub 2006 Nov 27. Eur Urol. 2007. PMID: 17157979 Review.
-
Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.Expert Opin Pharmacother. 2009 Dec;10(18):3103-11. doi: 10.1517/14656560903451682. Expert Opin Pharmacother. 2009. PMID: 19954278 Review.
Cited by
-
Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.Drugs Aging. 2012 Apr 1;29(4):259-73. doi: 10.2165/11597530-000000000-00000. Drugs Aging. 2012. PMID: 22390261 Review.
-
The Pharmacology of Visual Hallucinations in Synucleinopathies.Front Pharmacol. 2019 Dec 9;10:1379. doi: 10.3389/fphar.2019.01379. eCollection 2019. Front Pharmacol. 2019. PMID: 31920635 Free PMC article. Review.
-
Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.Int Urogynecol J. 2011 Aug;22(8):907-17. doi: 10.1007/s00192-011-1411-6. Epub 2011 Apr 6. Int Urogynecol J. 2011. PMID: 21468739 Review.
-
Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.Curr Urol Rep. 2011 Oct;12(5):351-7. doi: 10.1007/s11934-011-0198-9. Curr Urol Rep. 2011. PMID: 21607875 Review.
-
Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients.Neurol Sci. 2009 Apr;30(2):87-92. doi: 10.1007/s10072-009-0033-y. Epub 2009 Feb 20. Neurol Sci. 2009. PMID: 19229475 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources